Search results for "Lymphatic"

showing 10 items of 1179 documents

BRAF(V600E) MUTATION AND THE BIOLOGY OF PAPILLARY THYROID CANCER

2008

BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indi…

MaleCancer Researchendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.disease_causethyroidPapillary thyroid cancerSettore MED/13 - EndocrinologiaImmunoenzyme TechniquesEndocrinologythyroid cancerskin and connective tissue diseasesSicilyMicrodissectionBRAF(V600E)Univariate analysisMutationGeographyReverse Transcriptase Polymerase Chain ReactionThyroidBRAF V600; Papillary Thyroid CancerMiddle Agedhumanitiesmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyLymphatic MetastasisDisease ProgressionFemaleMicrodissectionProto-Oncogene Proteins B-rafPapillary thyroid cancer BRAF(V600E) thyroid thyroid cancerBRAF V600BiologyThyroid carcinomamedicineCarcinomaHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsneoplasmsDNA PrimersLasersPapillary thyroid cancer BRAFmedicine.diseaseCarcinoma Papillarydigestive system diseasesMutationCancer researchV600EFollow-Up StudiesPapillary Thyroid Cancer
researchProduct

Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration.

1990

This clinical trial was performed to study the effects of intravenously (IV) administered recombinant human (rh) erythropoietin (EPO) at escalating doses (150, 300, and 450 U/kg, administered as an IV bolus injection, twice weekly, for 6, 4, and 4 weeks, respectively) in five patients with low-grade non-Hodgkin's lymphoma (Ig NHL) and bone marrow involvement and one patient with multiple myeloma (MM). All patients were anemic due to underlying disease. None of the patients had a history of bleeding, hemolysis, renal insufficiency, or other disorders causing anemia in addition to bone marrow infiltrating malignancy. Endogenous EPO serum levels were significantly increased in all patients (7…

MaleCancer Researchmedicine.medical_specialtyAnemiaHematocritMalignancyGastroenterologyBone Marrowhemic and lymphatic diseasesInternal medicineNeoplasmsMedicineHumansErythropoiesisBlood CoagulationErythropoietinMultiple myelomaAgedClinical Trials as Topicmedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaAnemiaMiddle Agedmedicine.diseaseLymphomaHematopoiesisKineticsmedicine.anatomical_structureOncologyErythropoietinImmunologyFerritinsErythropoiesisFemaleBone marrowbusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms

2010

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2 V617F-negative myeloproliferative neoplasms

MaleCancer Researchmedicine.medical_specialtyGenotypejak2 mpl mutation myeloprolifertaive neoplasmPolymerase Chain ReactionPolymorphism Single NucleotideSettore MED/15 - Malattie Del SangueMyeloproliferative DisordersPolymorphism (computer science)hemic and lymphatic diseasesInternal medicineGenotypemedicineHumansGeneticsThrombopoietin receptorHematologyJanus kinase 2Myeloproliferative DisordersbiologyHaplotypefood and beveragesHematologyJanus Kinase 2Middle AgedOncologyHaplotypesMutation (genetic algorithm)MutationCancer researchbiology.proteinFemaleReceptors Thrombopoietinhormones hormone substitutes and hormone antagonists
researchProduct

Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization

2001

Structural alterations in 3q27 affecting the BCL6 locus are among the most frequent changes in B-NHL. The aim of the present study was to establish an interphase-FISH assay for the detection of all diverse BCL6 translocations in B-NHL. Two different approaches were tested, one using a PAC-clone spanning the major breakpoint region (MBR) of BCL6 (span-assay), and another using two BAC clones flanking the MBR (flank-assay). Interphase FISH with the span-assay detected the various BCL6 translocations in seven B-NHL cell lines. The dual-color flank-assay was evaluated in two laboratories independently: in normal controls, the cutoff level for false-positive signals was 2.6%, whereas the cutoff …

MaleCancer Researchmedicine.medical_specialtyLymphoma B-CellLymphomaMolecular Sequence DataTranslocationChromosomal translocationLocus (genetics)BiologyTranslocation GeneticFluorescenceChromosomesGeneticimmune system diseaseshemic and lymphatic diseasesmedicineHumansIn Situ Hybridization FluorescenceIn Situ HybridizationGeneticsGene Rearrangementmedicine.diagnostic_testBase SequenceBreakpointCytogeneticsB-CellBase Sequence; Chromosome Banding; Female; Gene Rearrangement; Humans; In Situ Hybridization Fluorescence; Karyotyping; Lymphoma B-Cell; Male; Molecular Sequence Data; Chromosomes Human Pair 3; Translocation GeneticHematologyGene rearrangementmedicine.diseaseMolecular biologyChromosome BandingOncologyChromosome 3KaryotypingPair 3FemaleChromosomes Human Pair 3TrisomyFluorescence in situ hybridizationHuman
researchProduct

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1994

BACKGROUND The influence of DNA content on prognosis in stomach cancer has been investigated rarely, and the results are controversial. METHOD The prognostic relevance of the DNA content and histomorphologic parameters was evaluated in 41 patients after resection of pancreatic cancer. RESULTS In the univariate analysis, the DNA content, tumor size, lymph node status, tumor stage, nuclear grade, and type of resection had a statistically significant influence on the prognosis. No association was found between the DNA content and the histomorphologic features. Apart from the operative procedure, the DNA content was the strongest indicator of prognosis in the multivariate analysis. CONCLUSIONS …

MaleCancer Researchmedicine.medical_specialtyPathologyPancreatic diseaseMultivariate analysisGastroenterologyPolyploidyPancreatectomyText miningPancreatic cancerInternal medicinemedicineHumansStomach cancerLymph nodeNeoplasm StagingCell NucleusUnivariate analysisbusiness.industryDNA NeoplasmPrognosismedicine.diseaseDiploidyPancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisMultivariate AnalysisLymph Node ExcisionFemalePancreasbusinessFollow-Up StudiesCancer
researchProduct

“Masked” Philadelphia chromosome resulting from a t(X;22) in chronic myeloid leukemia

1988

Abstract A rare cytogenetic finding in chronic myeloid leukemia is reported. It consisted in a “masked” Philadelphia chromosome, resulting from an unusual translocation between chromosomes #22 and X. The t(X;22) was present in 100% of direct and cultured bone marrow cell preparations. Chromosome #9 did not seem to be involved in the formation of the Ph marker. Involvement of the X chromosome in karyotypic changes of hematologic diseases, with particular respect to chronic myeloid leukemia, is discussed.

MaleCancer Researchmedicine.medical_specialtyX ChromosomeChromosomes Human Pair 22Chromosomal translocationBiologyPhiladelphia chromosomeTranslocation Genetichemic and lymphatic diseasesGeneticsmedicineHumansPhiladelphia ChromosomeMolecular BiologyBone marrow cellX chromosomeGeneticsCytogeneticsMyeloid leukemiaChromosomeMiddle Agedmedicine.diseaseMolecular biologyLeukemia MyeloidKaryotypingCancer Genetics and Cytogenetics
researchProduct

Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.

1996

Most patients with congenital hypogammaglobulinemia and absent B cells are males with X-linked agammaglobulinemia, which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are females with a similar disorder who do not have mutations in this gene. We studied two families with autosomal recessive defects in B-cell development and patients with presumed X-linked agammaglobulinemia who did not have mutations in Btk.A series of candidate genes that encode proteins involved in B-cell signal-transduction pathways were analyzed by linkage studies and mutation screening.Four different mutations were identified in the mu heavy-chain gene on chromosome 14. In one fa…

MaleCandidate geneGenetic LinkageDNA Mutational AnalysisConsanguinitymedicine.disease_causeConsanguinityGenetic linkageAgammaglobulinemiahemic and lymphatic diseasesmedicineBruton's tyrosine kinaseHumansLymphocyte CountGeneGeneticsChromosomes Human Pair 14MutationB-LymphocytesbiologyImmunoglobulin mu-ChainsChromosomeGeneral MedicinePedigreeRNA splicingMutationbiology.proteinFemaleThe New England journal of medicine
researchProduct

Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.

1999

Abstract Circulating plasma cells in 10 cases of reactive plasmacytosis had a shared phenotype with early plasma cell (CD19+CD38+ CD138+ CD40+CD45+ CD11a+ CD49e−CD56−). In most cases, a minor subpopulation of CD28+ plasma cells was also detected. Reactive plasma cells were highly proliferative, suggesting the presence of circulating progenitors (plasmablasts). After CD138+ plasma cell removal, highly proliferative CD138− plasmablasts differentiated into CD138+ plasma cells within a few days. This differentiation, which was associated with increased CD38 and decreased HLA-DR expression, was further confirmed by a large increase in intracellular Ig content (associated with Ig secretion) and w…

MaleCellular differentiationRemission SpontaneousApoptosisCD38Plasma cellBiochemistry0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesChildCells Cultured[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]0303 health sciencesbiologyAntibodies MonoclonalCell DifferentiationHematologyMiddle Agedmedicine.anatomical_structureFemaleAntibodyMultiple MyelomaAdultPlasma CellsImmunologyLymphocytosisCD19ImmunophenotypingImmunoglobulin kappa-Chains03 medical and health sciencesImmunoglobulin lambda-ChainsAntigens CD[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]medicineHumansProgenitor cellAgedRetrospective Studies030304 developmental biologyCD40Interleukin-6PlasmacytosisCell Biologymedicine.diseaseHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Immunologybiology.protein[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]030215 immunology
researchProduct

Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth : a possible role for exosomal disposal of miR-21

2015

// Simona Taverna 1 , Marco Giallombardo 1 , Marzia Pucci 1 , Anna Flugy 1 , Mauro Manno 2 , Samuele Raccosta 2 , Christian Rolfo 3 , Giacomo De Leo 1 , Riccardo Alessandro 1, 4 1 Dipartimento di Biopatologia e Metodologie Biomediche, Sezione di Biologia e Genetica, Universita di Palermo, Italy 2 Istituto di Biofisica, CNR, Palermo, Italy 3 Phase I - Early Clinical Trials Unit Oncology Department and Center of Oncological Research (CORE), University Hospital Antwerp & Antwerp University, Belgium 4 Istituto di Biomedicina e Immunologia Molecolare (IBIM), Consiglio Nazionale delle Ricerche, Palermo, Italy Correspondence to: Riccardo Alessandro, e-mail: riccardo.alessandro@unipa.it Keywords: e…

MaleCurcuminexosomes microRNAs CML curcumin miR-21exosomesMice SCIDBiologyTransfectionMiceRandom Allocationchemistry.chemical_compoundDownregulation and upregulationLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesmedicineAnimalsHumansCMLBiologyCell ProliferationCell growthTransfectionmedicine.diseaseXenograft Model Antitumor AssaysMolecular biologyMicrovesiclesmicroRNAsOncologychemistryCancer cellCurcuminmiR-21Human medicineK562 CellsResearch PaperChronic myelogenous leukemiaK562 cellsOncotarget
researchProduct

Periodontal changes during chronic benign granulocytopenia in childhood. A case report.

1975

The report describes two children with chronic benign granulocytopenia, suffering from gingivitis and marginal periodontitis in the deciduous dentition. The radicular areas of the attached gingiva were well delineated against the alveolar and papillary mucosa.

MaleDentistryChronic benign granulocytopeniaMarginal periodontitisGingivitisPeriodontal diseasehemic and lymphatic diseasesMedicineHumansTooth DeciduousChildPeriodontitisPeriodontitisbusiness.industryDeciduous dentitionmedicine.diseaseGingivitisRadiographystomatognathic diseasesChronic diseaseAttached gingivaChronic DiseasePeriodonticsmedicine.symptombusinessAgranulocytosisJournal of clinical periodontology
researchProduct